CAPITOL COUNSEL LLC

Lobbying for EMERGENT BIOSOLUTIONS · Bio pharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 15, 2025

Lobbying activity 1

Health Issues

Providing guidance on development, acquisition and stockpiling of medical countermeasures for the US government. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA). Funding for medical countermeasure enterprise including, SNS, BARDA and Project BioShield; State Opioid Response (SOR) Grant Funding; Substance Abuse and Mental Health Block Grant (SABG) funding. Naloxone access and awareness and opioid prescribing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.